Vemurafenib Salts for Enteroviral Infection Treatment (US12599591B2)
Summary
USPTO granted Patent US12599591B2 to Jyväskylän yliopisto for N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (vemurafenib) and pharmaceutical salts for treating enteroviral diseases. The patent contains 14 claims and is classified under CPC codes A61K 31/437 and A61P 31/16.
What changed
USPTO issued Patent US12599591B2 to Jyväskylän yliopisto (University of Jyväskylä) covering vemurafenib and pharmaceutical salts for use in treating enteroviral infections. The invention, developed by inventors Varpu Marjomäki, Mira Laajala, and Mari Martikainen, claims the compound known as vemurafenib in combination with pharmaceutical acceptable salts for this therapeutic use.
Pharmaceutical companies and researchers developing antiviral therapeutics should review this patent for potential licensing needs or freedom-to-operate concerns. The patent's issuance establishes exclusive rights in the US market for this indication, which may affect competitors working on similar enteroviral treatments.
What to do next
- Monitor patent database for related patents
- Review freedom-to-operate for enteroviral therapeutics
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Vemurafenib and salts thereof for use in the treatment of enteroviral infections
Grant US12599591B2 Kind: B2 Apr 14, 2026
Assignee
Jyväskylän yliopisto
Inventors
Varpu Marjomäki, Mira Laajala, Mari Martikainen
Abstract
The present invention provides N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide known as vemurafenib, and pharmaceutical salts thereof for use in the treatment of enteroviral diseases.
CPC Classifications
A61K 31/437 A61K 9/0053 A61K 9/2009 A61K 9/2013 A61K 9/2054 A61P 31/16 Y02A 50/30
Filing Date
2019-10-03
Application No.
17281650
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.